Form 4: Vertex Pharmaceuticals Executive Trades VRTX Stock
Statement of Changes in Beneficial Ownership
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, executed a sale of common stock under a pre-arranged trading plan.
Summary
- Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc., reported a transaction involving the company's common stock.
- The transaction, dated June 26, 2026, involved the disposition of 596 shares of common stock at a price of $482.50 per share.
- This sale was conducted under a Rule 10b5-1 trading plan, which was established on November 20, 2025.
- Following this transaction, Ms. Bozic beneficially owns 15,337 shares of Vertex Pharmaceuticals common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it reports a routine transaction under a pre-established trading plan, without indicating significant positive or negative developments for the company.
Negatives
- An executive sold a portion of their holdings in the company's stock.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a past transaction.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, indicates a structured approach to managing personal stock holdings, often employed to avoid perceptions of insider trading based on material non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan | Transaction executed under a company-approved trading plan established under Rule 10b5-1. | 2025-11-20 | Demonstrates adherence to compliance procedures for executive stock transactions, mitigating potential insider trading concerns. |
Stakeholder Impact
- Shareholders: The sale of stock by an executive may be perceived by some shareholders as a negative signal, although the use of a Rule 10b5-1 plan mitigates this concern by indicating the sale was pre-planned and not based on current material non-public information.
Key Dates
| Date | Description |
|---|---|
| 2025-11-20 | Date trading plan under Rule 10b5-1 was entered into. |
| 2026-06-26 | Transaction date for the sale of common stock. |
| 2026-06-30 | Date the statement was signed. |
Keywords
Vertex Pharmaceuticals, VRTX, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Carmen Bozic, Executive Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.